TY - JOUR T1 - CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators JF - medRxiv DO - 10.1101/2021.01.31.21250702 SP - 2021.01.31.21250702 AU - Nicholas C. Cullen AU - Shorena Janelidze AU - Sebastian Palmqvist AU - Erik Stomrud AU - Niklas Mattsson-Carlgren AU - Oskar Hansson Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/01/2021.01.31.21250702.abstract N2 - Objective Shorter Aβ species might modulate disease progression in Alzheimer’s disease (AD). Here we studied whether Aβ38 levels in cerebrospinal fluid (CSF) are associated with risk of developing AD dementia and cognitive decline.Methods CSF Aβ38 levels were measured in 656 individuals across two clinical cohorts – the Swedish BioFINDER study and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Cox regression models were used to evaluate the association between baseline Aβ38 levels and risk of AD dementia in AD-biomarker positive individuals (AD+; determined by CSF P-tau/Aβ42 ratio) with subjective cognitive decline (SCD) or mild cognitive impairment (MCI). Linear mixed effects models were used to evaluate the association between baseline Aβ38 levels and cognitive decline as measured by MMSE in AD+ participants with SCD, MCI or AD dementia.Results In the BioFINDER cohort, high Aβ38 levels were associated with slower decline in MMSE (β = 0.30 points / sd., P = 0.001) and with lower risk of conversion. To AD dementia (HR = 0.83 per sd., P = 0.03). In the ADNI cohort, higher Aβ38 levels were associated with less decline in MMSE (β = 0.27, P = 0.01), but not risk of conversion to AD dementia (P = 0.66). Aβ38 levels in both cohorts remained significantly associated with both outcomes when adjusted for CSF P-tau levels and remained associated with cognition when adjusted for CSF Aβ42 levels.Conclusions Higher CSF Aβ38 levels are associated with lower risk of AD-related changes in two independent clinical cohorts. These findings may have implications for γ-secretase modulators as potential disease-altering therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03174938Funding StatementWork at the authors' lab is funded by Knut and Alice Wallenberg Foundation, the Medical Faculty at Lund University, Region Skane, the European Research Council, the Swedish Research Council, the Strategic Research Area MultiPark at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, The Parkinson foundation of Sweden, The Parkinson Research Foundation, the Skane University Hospital Foundation, the Swedish federal government under the ALF agreement, the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, and the Bundy Academy.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants gave written informed consent. Ethical approval was given by the Regional Ethical Committee in Lund, Sweden.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request. ER -